Red Oak Psychiatry Associates
- Consultant: AstraZeneca LP; Bristol-Myers Squibb; Cephalon, Inc.; Cyberonics, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Novartis Pharmaceutical Corporation; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Pfizer Inc; Sepracor Inc.; Shire Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.; UCB Pharma, Inc; Validus Pharmaceuticals; Wyeth Pharmaceuticals; sanofi-aventis
- Research Support: Abbott Laboratories; Alkermes, Inc.; AstraZeneca LP; Bristol-Myers Squibb; Cephalon, Inc.; Cyberonics, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Neurocrine Biosciences; Neuropharm Group plc; New River Pharmaceuticals; Novartis Pharmaceutical Corporation; Organon Pharmaceuticals USA Inc.; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Pam Labs; Pfizer Inc; Seaside Therapeutics; Sepracor Inc.; Shire Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.; UCB Pharma, Inc; Validus Pharmaceuticals; Wyeth Pharmaceuticals; sanofi-aventis
- Speakers Bureau: Alkermes, Inc.; AstraZeneca LP; Bristol-Myers Squibb; Cephalon, Inc.; Cyberonics, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; JDS Pharmaceuticals; Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceutical Corporation; Noven Pharmaceuticals; Organon Pharmaceuticals USA Inc.; Pam Labs; Pfizer Inc; Schwarz; Sepracor Inc.; Shire Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.; UCB Pharma, Inc; Validus Pharmaceuticals; Wyeth Pharmaceuticals; sanofi-aventis